* Ardelyx Inc (NASDAQ: ARDX) (reported positive results from a late-stage of its lead compound tenapanor in combination with phosphate binders to treat
hyperphosphatemia in patients with chronic kidney disease on dialysis)
Ardelyx reported results from AMPLIFY, a pivotal Phase 3 study of tenapanor in combination with phosphate binders in patients with chronic kidney disease, or CKD, on dialysis whose
hyperphosphatemia was not previously controlled with binders alone.
KEYWORDS: Tumor lysis syndrome, hyperuricemia,
hyperphosphatemia, hypocalcemia, acute kidney injury.
Iron Overload: Increases in serum ferritin and transferrin saturation (TSAT) were observed in clinical trials with AURYXIA in patients with chronic kidney disease (CKD) on dialysis treated for
hyperphosphatemia, which may lead to excessive elevations in iron stores.
Auryxia is the only oral iron tablet approved in the US to treat non-dialysis-dependent-chronic kidney disease adult patients for iron deficiency anemia, and dialysis-dependent CKD adult patients for
hyperphosphatemia.
Sodium phosphate enemas and some rodenticides can also cause
hyperphosphatemia. Hyperthyroidism in cats may cause an increase in phosphate, as thyroxin (thyroid hormone) can interfere with renal clearance of phosphate.
Patients with HFTC usually present with
hyperphosphatemia and tumor-like soft tissue calcifications.
M2 EQUITYBITES-February 8, 2019-Ardelyx Inc begins Phase 2 clinical study of tenapanor for the treatment of
hyperphosphatemia dialysis patients in Japan
Global Banking News-February 8, 2019-Ardelyx Inc begins Phase 2 clinical study of tenapanor for the treatment of
hyperphosphatemia dialysis patients in Japan
Keryx's Auryxia (ferric citrate) is a US Food and Drug Administration -approved medicine to treat dialysis dependent CKD patients for
hyperphosphatemia and non-dialysis dependent CKD patients for iron deficiency anemia.
According to the K/DOQI guidelines, we considered hypocalcemia as a total serum calcium level of <8.4 mg/dl,
hyperphosphatemia as a serum phosphorus level of >5.5 mg/L, and high iPTH as a serum iPTH level of >300 pg/ml.[5] Associated parameters were compared between the two groups, and then overall data in Hebei province were compared to those reported in DOPPS4[6],[7] and Chinese DOPPS.[8]
PHP is a rare condition characterized by a biochemical pattern of hypocalcemia,
hyperphosphatemia, and increased PTH concentrations (2).